NCI CTC

The Common Toxicity Criteria is a standard language for reporting adverse events occurring in cancer clinical trials. The National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) developed the original CTC in 1982. The CTC was revised in 1998 in order to promote accuracy and precision of reporting, and to avoid development of non-standard adverse event nomenclature or inconsistent definitions for severity.
The NCI terms are a set of medical terms very useful for the classification of adverse events related to cytotoxic drugs. These terms are not international codes for reporting adverse events to the Health Authorities. They are very frequently used in handling adverse events from oncology trials. The coding should not be performed with the NCI terms but they could be employed in establishing a relationship between these terms and the corresponding MedDRA terms since the MedDRA dictionary is the internationally agreed terminology for coding of adverse drug reactions or adverse events following the use of new agents. Some mapping documents may be accessed, and downloaded through the RTOG Web site (

http://www.rtog.org/members/toxicity/imttox.html). The CTCAE Mapping documents provide additional information to support the implementation of CTCAE version 3.0 and the transition from CTC version 2.0 (MedDRA version 5.0) to CTCAE version 3.0 (MedDRA v6.0).

Common Toxicity Criteria Document for Adverse Events v2.0 (CTCAE) (PDF)
Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (PDF)

CTCAE Mapping Documents:

1. CTC version 2.0 to CTCAE version 3.0 document
2. CTCAE version 3.0 to CTC version 2.0 document
3. CTC version 2.0 (MedRA 5.0) to CTCAE version 3.0 (MedRA 6.0)
4. CTC version 2.0 to CTCAE version 3.0 Grade Mapping (Excel)
5. CTC version 2.0 to CTCAE version 3.0 Mapping with Short Name


For more information about Pharmadhoc and its services, please feel free to contact M. Azzouzi at +33 (0)8 71 76 88 17,
or send an email to Pharmadhoc